Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib versus placebo in residual or recurrent IDH-mutant grade 2 glioma
NL-OMON59955Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioma, Oligodendroglioma (OG) and astrocytoma comparing Vorasidenib with Placebo (2 arms). Primary endpoint: Radiographic progression-free survival. Started Aug 2020; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
gliomaOligodendroglioma (OG)astrocytoma
Beyond the preview
Go deeper on NL-OMON59955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59955.